Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021)
Ginkgo Bioworks Holdings' (DNA) quarterly Preferred Stock Liabilities came in at $1.5 billion in Q2 2021, down 6.79% on a QoQ basis from $1.6 billion in Q1 2021.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 1 years of Preferred Stock Liabilities data on file, last reported at $1.5 billion in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 427.83 Mn | 343.30 Mn | 18.44 Mn | - |